Utility of novel androgen receptor therapies in the real world: A nuanced approach

Mallika Dhawan, Charles J. Ryan

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Abiraterone and enzalutamide are in widespread clinical use because of their favorable safety and efficacy. Nonetheless, even with newer agents, resistance develops overtime. In this review, we discuss mechanisms of resistance to these newer agents as well as novel therapeutic agents. We also review the literature to help clinicians decide which agent to begin with and when to stop or switch androgen receptor agents.

Original languageEnglish (US)
Pages (from-to)340-347
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume34
Issue number8
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Keywords

  • Androgen receptor therapies
  • Novel therapies
  • Prostate cancer
  • Resistance mechanisms

Fingerprint

Dive into the research topics of 'Utility of novel androgen receptor therapies in the real world: A nuanced approach'. Together they form a unique fingerprint.

Cite this